

Semaglutide (Wegovy®) for Managing Overweight and Obesity SWL Position statement (Updated October 2024)

In NHS South West London, prescribing of Semaglutide (Wegovy®) for weight loss is restricted to tier 3 and 4 weight management services, in line with the criteria set and therefore should not be issued in primary care.

On 8 March 2023, the National Institute for Health and Care Excellence (NICE) published [guidance recommendations \[TA875\] on semaglutide for managing overweight and obesity](#) within specialist weight management services (including Tier 3 and 4), in line with specific criteria.

At the time of the NICE publication, Wegovy®, was not commercially available for NHS use in the UK. From September 2023, Novo Nordisk, the manufacturer of Wegovy® confirmed supplies would be made available to the NHS a controlled and limited launch.

SWL ICB in conjunction with our locally commissioned weight loss specialist service has now refreshed the existing weight management pathways and referral guidelines to incorporate Wegovy® alongside the prescribing of Liraglutide (Saxenda®).

The prescribing of both Wegovy® and Saxenda® are restricted to SWL commissioned tier 3 and 4 weight management services in line with [NICE TA875](#) and [TA664](#) respectively.

Prescriptions of all liraglutide or semaglutide-containing formulations for the management of weight should not be issued in primary care.

Clinicians can access the local tier 3 and 4 weight management referral form and pathway for Wegovy® and liraglutide via DXS.

Update on Oviva Specialist Tier 3 Weight Management services

We are aware that many practices have been contacted by Oviva to refer patients to their remote NHS Tier 3 Weight Management programme, that includes supply of GLP-1 medications. Currently they are only offering Wegovy.

SWL ICB currently does not commission Oviva's Tier 3 weight management services, however as the provider holds a qualifying NHS standard contract in England, it has been made available as an option on the electronic referral system (eRS) as national service offering under patients right to choice.

NHS England's choice team are looking into this service offering and the ICB will provide further communication once further assurances regarding this provider has been clarified.

Document History

Version 2.3 (correction of typo)
Author: SWL ICB Medicines Optimisation Team
Approved by: SWL IMOC
Approval Date: October 2024
Review Dates: October 2025